Literature DB >> 12879735

[Indications and practical management of parenteral iron therapy].

Markus Kosch1, Roland M Schaefer.   

Abstract

Absolute or functional iron deficiency is a common problem in chronic disease which may lead to iron-deficient erythropoesis. Moreover, lack of available iron is the most common reason for unresponsiveness to epoetin in patients on chronic dialysis. Measurements of serum ferritin, transferrin saturation and percentage of hypochromic red blood cells allow the assessment of iron status. Lack of iron resorption and dose-dependent side-effects limit oral supplementation in a number of patients. Several iron preparations are available for intravenous substitution, especially the newly registered iron-saccharose offers safe and reliable iron supplementation and reduces the risk of anaphylaxis and iron toxicity. This review discusses new guidelines concerning diagnosis of iron status, indication for therapy and application of intravenous iron preparation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12879735     DOI: 10.1007/bf03040356

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  21 in total

Review 1.  How to diagnose and correct iron deficiency during r-huEPO therapy--a consensus report.

Authors:  W H Hörl; I Cavill; I C MacDougall; R M Schaefer; G Sunder-Plassmann
Journal:  Nephrol Dial Transplant       Date:  1996-02       Impact factor: 5.992

2.  Adverse reactions to total-dose infusion of iron dextran.

Authors:  A Shimada
Journal:  Clin Pharm       Date:  1982 May-Jun

Review 3.  Toxicity of parenteral iron dextran therapy.

Authors:  D L Burns; J J Pomposelli
Journal:  Kidney Int Suppl       Date:  1999-03       Impact factor: 10.545

Review 4.  Anemia in critical illness.

Authors:  K U Eckardt
Journal:  Wien Klin Wochenschr       Date:  2001-02-15       Impact factor: 1.704

Review 5.  [Iron, infection and anemia--a classical triad].

Authors:  Günter Weiss
Journal:  Wien Klin Wochenschr       Date:  2002-06-14       Impact factor: 1.704

6.  Impairment of phagocyte oxidative metabolism in hemodialyzed patients with iron overload.

Authors:  J Flament; M Goldman; Y Waterlot; E Dupont; J Wybran; J L Vanherweghem
Journal:  Clin Nephrol       Date:  1986-05       Impact factor: 0.975

7.  'Oversaturation' of transferrin after intravenous ferric gluconate (Ferrlecit(R)) in haemodialysis patients.

Authors:  A L Zanen; H J Adriaansen; E F van Bommel; R Posthuma; G M Th de Jong
Journal:  Nephrol Dial Transplant       Date:  1996-05       Impact factor: 5.992

Review 8.  Safety aspects of parenteral iron in patients with end-stage renal disease.

Authors:  G Sunder-Plassmann; W H Hörl
Journal:  Drug Saf       Date:  1997-10       Impact factor: 5.606

9.  Safety of intravenous injection of iron saccharate in haemodialysis patients.

Authors:  G Sunder-Plassmann; W H Hörl
Journal:  Nephrol Dial Transplant       Date:  1996-09       Impact factor: 5.992

10.  The hypochromic red cell: a new parameter for monitoring of iron supplementation during rhEPO therapy.

Authors:  R M Schaefer; L Schaefer
Journal:  J Perinat Med       Date:  1995       Impact factor: 1.901

View more
  1 in total

Review 1.  Molecular and clinical aspects of iron homeostasis: From anemia to hemochromatosis.

Authors:  Manfred Nairz; Günter Weiss
Journal:  Wien Klin Wochenschr       Date:  2006-08       Impact factor: 1.704

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.